Can-Fite BioPharma Ltd. (CANF) is a publicly traded company in the Healthcare — Biotechnology industry listed on AMEX. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
Can-Fite BioPharma Ltd., an Israeli clinical-stage biopharmaceutical company, specializes in the creation of small molecule therapeutic products. These treatments target a range of conditions including various cancers, inflammatory liver disorders, and erectile dysfunction. Its primary drug candidate, Piclidenoson, has successfully advanced through Phase III clinical trials for psoriasis and completed Phase II trials for COVID-19.
Analysis Summary
Can-Fite BioPharma Ltd. reported revenue of $408212 in the most recent fiscal year, growing at a 5-year CAGR of -11.8%.
Trailing-twelve-month margins: gross margin 100.0%, operating margin -24.6%, net margin -24.3%.
At the current price of $2.24, CANF has negative trailing earnings (P/E not meaningful) and an ROE of -201.06%. Market capitalisation stands at $3M.
Balance sheet quality for CANF: current ratio of 3.5, net cash position of $8.5M. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Price
| Price | $2.24 |
| Market Cap | $3M |
| Exchange | AMEX |
| Country | IL |
Valuation Ratios
| Price / Book | 0.46 |
| EV / EBITDA | 0.05 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -201.06% |
| Return on Invested Capital | -145.49% |
| Return on Assets | -103.30% |
| Gross Margin | 100.00% |
| Operating Margin | -2456.79% |
| Net Margin | -2426.67% |
Financial Health
| Debt / Equity | 0.01 |
| Current Ratio | 3.46 |
What to look at in Biotech
Most small biotechs lose money. Analysing them with P/E makes no sense — look at cash and pipeline.
- Cash Runway — Months of cash at current burn rate. <18 months = urgent dilution risk
- Annual cash burn — Rate at which they burn operating cash. Compare with cash position to project runway
- Total Debt — Biotech with no revenue + debt = recipe for bankruptcy
- R&D / Market cap — How much they invest in pipeline vs the company value — research-intensity indicator
- Market cap / Cash — If it trades near its cash, the market assigns ~0 value to the pipeline — opportunity or trap
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| CANF | Can-Fite BioPharma Ltd. | $3M | 0.46 | -201.1% | |
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $131.8B | |||
| VRTX | Vertex Pharmaceuticals Incorporated | $130.3B | 29.68 | 6.45 | 23.3% |
| 0R2M.L | Regeneron Pharmaceuticals, Inc. | $84.0B | |||
| REGN | Regeneron Pharmaceuticals, Inc. | $79.8B | 18.79 | 2.57 | 13.8% |
| ARGX | argenx SE | $61.2B | 36.30 | 7.40 | 21.7% |
| MRNA | Moderna, Inc. | $57.8B | 1.34 | -39.2% | |
| RVMD | Revolution Medicines, Inc. | $41.7B | 15.96 | -96.4% |
Price Performance
| 1 month | -35.07% |
| 3 months | -24.83% |
| Year-to-date | -44.00% |
| 1 year | -82.77% |
| 3 years | -95.76% |
| 5 years | -99.36% |
52-Week Range
| 52-week High | $13.40 |
| 52-week Low | $2.16 |
| Avg Volume (90d) | 1.2M |
Related companies: BDRX · CLDI · CMND · CNSP · GRI · JAGX · KZIA
Explore sector: Healthcare · Biotechnology
More sections of CANF: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks